Focus: Zoll is a medical device leader headquartered in San Jose, CA, specializing in defibrillators, cardiac monitoring, and emergency care devices across cardiovascular, neurology, and respiratory segments. With 5,000+ employees and 44 years of operating history, it is a mature, established player in acute-care medical technology.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Hot — 209 jobs added in 30d
Net +84 (209 new, 125 removed). Aggressive expansion phase.
Recent layoff filing — 96 affected
Source: state DOL filings via Big Local News
Zoll offers stable employment in a mission-critical device company but carries regulatory execution risk and modest innovation velocity—suitable for operationally-minded professionals but requires clarity on FDA remediation timeline.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Zoll
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zoll's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Zoll receives FDA warning letter over quality concerns - MedTech Dive
Zoll receives FDA warning letter over quality concerns MedTech Dive
Zoll faces FDA warning letter related to quality, reporting processes - MassDevice
Zoll faces FDA warning letter related to quality, reporting processes MassDevice
FDA cites companies for CGMP violations, telehealth firms for illegally marketing GLP-1 drugs - RAPS
FDA cites companies for CGMP violations, telehealth firms for illegally marketing GLP-1 drugs RAPS
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients - Medscape
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients Medscape
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection - PharmiWeb.com
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection PharmiWeb.com
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation.
The impact of defibrillation current and pad position on return of spontaneous circulation during refractory ventricular fibrillation.
Source: FDA Warning Letters database
Dual regulatory and operational headwinds (FDA warning + recent facility closure) pose immediate risk to job security and organizational morale—monitor remediation progress closely.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo